Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...

Meanwhile, Eli Lilly's IL-23 inhibitor mirikizumab is also a potential rival, having shown potential in mid-stage trials and advanced into phase 3 testing. Skyrizi is a key part of AbbVie's ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Diagnosis of Crohn's disease (CD) is often challenging and requires the utmost precision and perseverance in defining location, extent, severity and type of disease (inflammatory vs stricturing ...

After hours: March 12 at 7:55:02 PM EDT Loading Chart for BBWI ...